	US 12,377,118 B2
	Nanoparticle constructs for systemic co-delivery of anti-tumor agents
Efstathios Karathanasis, Solon, OH (US); Prabhani Atukorale, Cleveland, OH (US); Wyatt Becicka, Cleveland, OH (US); and Peter Bielecki, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Aug. 10, 2020, as Appl. No. 16/989,473.
Claims priority of provisional application 62/884,963, filed on Aug. 9, 2019.
Prior Publication US 2021/0038633 A1, Feb. 11, 2021
Int. Cl. A61K 31/739 (2006.01); A61K 9/127 (2025.01); A61K 31/7016 (2006.01); A61K 31/7084 (2006.01); A61K 47/24 (2006.01)

CPC A61K 31/739 (2013.01) [A61K 9/127 (2013.01); A61K 31/7016 (2013.01); A61K 31/7084 (2013.01); A61K 47/24 (2013.01)]

27 Claims

1. An immuno-nanoparticle construct for systemic administration comprising:

a nanoparticle carrier;

a (STING) pathway agonist; and

a (TLR4) agonist, wherein the STING pathway agonist and the TLR4 agonists are co-loaded into the nanoparticle carrier.